Home/Health Plans/Employers/OnTrak Members/Contact Us
/
         
Blog Home  
  » Home  
  Recent Posts  
   
 
  Blog Calendar  
 
SuMoTuWeThFrSa
   1234
567891011
12131415161718
19202122232425
262728293031 
 
  Catasys Newsletter  
  Get the latest in healtcare news. » Sign Up Now  

Welcome to the Catasys On Healthcare Blog
Substance dependence drives significant health care costs for payors through a combination of factors that include acute inpatient utilization and unaddressed co-morbidities. The Substance Dependence problem is pervasive, largely untreated and costly. Stay informed on these topics by visiting our blog periodically. You can also sign up for the Catasys On Healthcare Newsletter to receive the latest in health care news. » Sign Up for Newsletter


Drug Seeking Behavior in ER Doubles

Catasys Health - Thursday, October 28, 2010

Drug Seeking Behavior in ER Doubles, Feeds Growing Addiction to Pain Pills -- Emergency rooms continue to become a major resource for pain medication addicts; By MIKAELA CONLEY, ABC News Medical Unit -- Oct. 28, 2010 » More


8 Drivers Impacting Cost Savings

Catasys Health - Thursday, September 23, 2010

Catasys On Healthcare September 2010 Newsletter
This edition of the Catasys newsletter outlines 8 drivers impacting cost savings from your substance dependent population. Surprisingly, national averages show $160 million in claims are incurred by substance dependent members in a 1 million member health plan. The majority of these costs are medical, driven by the consequences of substance abuse (and are mitigated if the substance abuse is successfully addressed).  » More


Cutting Edge Treatment for Substance Dependence for Health Plans

Catasys Health - Wednesday, December 16, 2009
For every 1 million members in a health plan, approximately $160 million in claims are incurred by members diagnosed with Substance Dependence. Most health plans have realistic cost savings opportunities in the millions of dollars. Our Medical Economics group can demonstrate specific savings opportunities for health plans with respect to both medical and behavioral costs.

The OnTrak program addresses many of the challenges experts highlight within the existing treatment paradigm for substance dependence. Specifically, OnTrak» More

Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy of Flumazenil and Gabapentin in Reducing Craving and Use During use during Initial Treatment of Methamphetamine Dependence

Catasys Health - Wednesday, November 25, 2009

Harold Urschel, Research Across America, Dallas, Texas
Published in the Journal of Psychopharmacology, November 25, 2009
 » More


Catasys Enters Into Agreement with Ford Motor Company

Catasys Health - Thursday, September 17, 2009
LOS ANGELES--(BUSINESS WIRE) -- Sep. 17, 2009 -- Catasys, Inc. announced today that the Company has entered into a three year agreement with Ford® Motor Company to provide the OnTrak integrated substance dependence solution to Ford’s hourly employees in Michigan enrolled in the National PPO and who meet certain criteria. Eligible employees struggling with alcoholism, stimulant and opiate dependence will be covered under the program, which contains medical interventions, psychosocial therapy and care coaching components across 52 weeks. The Company will conduct direct outreach to enroll qualified members, and will also work with UAW-Ford and Ford’s EAP program to ensure the most beneficial treatment pathway for members. Contractual revenues from the agreement are based on a combination of monthly fees for the member population for Catasys, with additional monthly fees for members enrolled into the Catasys program. Operational implementation is expected to begin shortly, and the program is anticipated to launch in the fourth quarter of 2009.

“We are pleased by the level of support we received from UAW-Ford and Ford’s management personnel,” said Rick Anderson, Catasys’ President and COO. “We have realigned our company and developed Catasys for the managed care market, and it is rewarding to have a new agreement that further publicly validates our product and business model. Ford’s desire to improve employee care and productivity demonstrates a significant opportunity for health plans to provide their customers the Catasys solution.”

Various studies, research and other resources demonstrate that:
 » More

Raymond Anton, Medical University of South Carolina, Charleston, SC

Catasys Health - Saturday, August 01, 2009

Randomized, Stratified, Double-Blind, Placebo-Controlled Trial of Flumazenil and Gabapentin for the Treatment of Alcohol Dependence
Published in the Journal of Clinical Psychopharmacology, August 2009; 29(4):334-342.

The OnTrak Medical Treatment Program achieved a significant reduction in use and cravings among members with symptoms of alcohol withdrawal (>6 CIWA) when compared to placebo.

Among members with more symptoms of alcohol withdrawal, the Prometa group experienced:
 » More




| 1 |

 

 
  Tags
 
addiction behavioral healthcare suboxone emergency room craving score behavioral health health reform pain pills PTSD hospital physician- patient relations drug use recovery chronic pain stratified behavioral health care services reducing craving medical and behavioral costs SD health insurance SD members methadone meth Opioid Prescribing Health Care Utilization heroin methamphetamine dependence reduction in craving opiates placebo-controlled CIWA ER marijuana depression screening cigarettes ADHD over-the-counter substances binge drinking UnitedHealthcare smoking codeine prescriptions treatment medical sobriety health plan Journal of Psychopharmacology predictive modeling muscle relaxant depression anxiety drug addiction recovery network trauma alcohol dependence drug overdose stimulants high-utilizing psychosocial opioid antagonist post-traumatic stress disorder facebook social network naloxone overdose buprenorphine medical costs care coaching nicotine primary care addiction treatment withdrawal substance use disorder substance dependence costs flumazenil health insurance cocaine alcohol drinking reduction in use urine drug screen Harold Urschel behavioral healthcare services cocaine treatment opioid abuse opioid fentanyl identification behavioral health care opiod-based Raymond Anton mental health placebo percocet mental illness sober ADD opiod abuse hospitalizations morphine opioid-drug interactions painkillers prometa drug abuse relapse vivitrol OxyContin data mining gabapentin oxycodone drug addicts drug treatment narcotic alcohol treatment double-blind alcohol sugar stress communication Co Occurring Disorders bipolar disorder opioid overdose drinking vicodin hydrocodone Opioid Medications diabetes relapse prevention Catasys alcoholism pain killers randomized OnTrak pain medication contract Research Across America methamphetamine substance dependence addict dependence issues craving Opioid Treatment substance dependence health insurance
  Call Us Today
  866-517-1414
         
 
 
Home/News/Press/Investor Relations/Careers/BlogContact Us/Site Index/Privacy Policy/Photo Disclaimer
 
  Copyright © 2013 Catasys. All rights reserved. | 11150 Santa Monica Blvd., Suite 1500, Los Angeles, California 90025 | Toll Free: 1-866-517-1414